Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Surrogate returned 18 record(s)
|
|
Monday, 07/30/2018
|
Inference on Treatment Effect Modification by Marker Response in a Baseline Surrogate Measure Three-Phase Sampling Design
Michal Juraska, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center; Peter Gilbert, Fred Hutchinson Cancer Research Center
10:50 AM
|
A Unified Approach to the Statistical Evaluation of Differential Vaccine Efficacy
Erin Gabriel, Karolinska Institute; Dean Follmann, NIAID
11:20 AM
|
An Analysis of MIMIC Data for Potential Surrogate Markers for Vaccine Development
Robert Small, Sanofi Pasteur; Pauline Jurvilliers, Sanofi Pasteur
11:20 AM
|
Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
3:05 PM
|
|
Tuesday, 07/31/2018
|
Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies
Jiabu Ye, AstraZeneca; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca
|
Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
|
Neutron Capture Cross Sections for Unstable Nuclei with Surrogate Reaction Data
Kassie Fronczyk, Lawrence Livermore National Laboratory; Jutta Escher, Lawrence Livermore National Laboratory
9:05 AM
|
Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies
Jiabu Ye, AstraZeneca; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca
9:45 AM
|
On the Relationship Between the Causal-Inference and Meta-Analytic Paradigms for the Evaluation of Surrogate Endpoints
Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven
10:35 AM
|
Assessment of Biomarkers and Surrogate Endpoints in Drug Development
Ivan Chan, AbbVie Inc; Shu-Chih Su, Merck Research Labs
10:55 AM
|
Limitations of Progression Free Survival as a Surrogate Marker for Overall Survival in Oncology Trials
Robin Mogg, Merck Research Laboratories; Yiwei Zhang, Merck Research Laboratories
11:15 AM
|
Identifying and Validating Surrogate Endpoints for Overall Survial (OS) in Metastatic Castration-Resistant Prostate Cancer
Xiaowei Guan, Pfizer, Inc.; Michelle Casey, Pfizer, Inc.; De Phung, Astellas Pharma, Inc. ; Suha Sari, Pfizer, Inc.; Eren Demirhan, Pfizer, Inc.
11:35 AM
|
|
|
